https://nvp-lde225antagonist.c....om/how-do-activity-p
Due to the emergence of fluoroquinolone resistance, handling of E. coli PJIs happens to be difficult and it is related to large therapy failure rates. We evaluated the efficacy of a newly isolated bacteriophage ɸWL-3 as a therapeutic agent in combination with ciprofloxacin, fosfomycin, gentamicin, meropenem or ceftriaxone against biofilm of a ciprofloxacin/ceftriaxone-resistant E. coli stress and the ATCC 25922 reference stress. ɸWL-3 was characterised in terms of virion m